Business Description
MorphoSys AG
ISIN : DE0006632003
Compare
Compare
Traded in other countries / regions
MOR.AustriaMOR.GermanyMOR.Switzerland0NDV.UKMPSYY.USA IPO Date
1999-03-09Description
MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.82 | |||||
| Equity-to-Asset | 0.04 | |||||
| Debt-to-Equity | 2.9 | |||||
| Debt-to-EBITDA | 1.54 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 0.46 | |||||
| Beneish M-Score | -1.82 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 53.1 | |||||
| 3-Year EPS without NRI Growth Rate | -10.7 | |||||
| 3-Year FCF Growth Rate | -61 | |||||
| 3-Year Book Growth Rate | -28.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.6 | |||||
| Quick Ratio | 3.46 | |||||
| Cash Ratio | 3 | |||||
| Days Inventory | 153.46 | |||||
| Days Sales Outstanding | 106.38 | |||||
| Days Payable | 555.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.5 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 79.36 | |||||
| Operating Margin % | -74.29 | |||||
| Net Margin % | -24.36 | |||||
| ROE % | -79.06 | |||||
| ROA % | -3.04 | |||||
| ROIC % | 11.16 | |||||
| ROC (Joel Greenblatt) % | 356.83 | |||||
| ROCE % | 8.36 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.79 | |||||
| PB Ratio | 8.61 | |||||
| EV-to-EBIT | 1.83 | |||||
| EV-to-EBITDA | 1.78 | |||||
| EV-to-Revenue | 1.09 | |||||
| EV-to-FCF | -1.92 | |||||
| Price-to-Median-PS-Value | 0.13 | |||||
| Earnings Yield (Greenblatt) % | 54.64 |
Balance Sheet Breakdown
Cashflow Statement Breakdown
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
MorphoSys AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil CHF) | 295.531 | ||
| EPS (TTM) (CHF) | -10.525 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (CHF) | 0 | ||
| 20-Day SMA (CHF) | 102 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (CHF) | 102 - 102 | ||
| Shares Outstanding (Mil) | 34.16 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
MorphoSys AG Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
MorphoSys AG Stock Events
| Event | Date | Price(CHF) | ||
|---|---|---|---|---|
| No Event Data | ||||
MorphoSys AG Frequently Asked Questions
What is MorphoSys AG(XSWX:MOR)'s stock price today?
The current price of XSWX:MOR is CHF102.00. The 52 week high of XSWX:MOR is CHF102.00 and 52 week low is CHF102.00.
When is next earnings date of MorphoSys AG(XSWX:MOR)?
The next earnings date of MorphoSys AG(XSWX:MOR) is 2023-08-09.
Does MorphoSys AG(XSWX:MOR) pay dividends? If so, how much?
MorphoSys AG(XSWX:MOR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers